- Home
- NUW vs TLSI Comparison
NUW vs TLSI Comparison
Compare NUW & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | TLSI |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.9M | 274.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NUW | TLSI |
|---|---|---|
| Price | $14.48 | $4.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 45.3K | ★ 125.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,207,000.00 |
| Revenue This Year | N/A | $55.47 |
| Revenue Next Year | N/A | $40.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $12.45 | $3.42 |
| 52 Week High | $14.44 | $7.95 |
Technical Indicators
Market Signals| Indicator | NUW | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 32.22 |
| Support Level | $14.23 | $5.24 |
| Resistance Level | $14.55 | $5.87 |
| Average True Range (ATR) | 0.11 | 0.37 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 79.43 | 2.71 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.